eviQ Cancer Treatments Online: Providing evidence-based information to improve cancer patient outcomes

IF 1.4 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2024-04-17 DOI:10.1111/ajco.14067

Julia V. Shingleton, Brooke W. Stapleton, Aisling P. Kelly, Robyn L. Ward, Cynthia L. Lean, Shelley A. Rushton, Tracey A. O'Brien

{"title":"eviQ Cancer Treatments Online: Providing evidence-based information to improve cancer patient outcomes","authors":"Julia V. Shingleton, Brooke W. Stapleton, Aisling P. Kelly, Robyn L. Ward, Cynthia L. Lean, Shelley A. Rushton, Tracey A. O'Brien","doi":"10.1111/ajco.14067","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To understand the current usage of eviQ Cancer Treatments Online (www.eviQ.org.au), an Australian, open-access website providing evidence-based and consensus-driven cancer treatment protocols and information, and the extent to which it is meeting its intended outcomes and providing value to its users.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A mixed-method evaluation was conducted in 2020−2022 which included a review of key program documentation and website usage data, and delivery of a focused online survey to its users.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In 2022, 329 clinicians representing all Australian states and territories contributed to eviQ content development and review. eviQ content continues to grow with a 15.2% increase in total content from 2019 to 2022.</p>\n \n <p> eviQ website users continue to grow with 90,000 total monthly users in 2022, representing a 166% increase from 2018. The proportion of international users compared to Australian users continues to grow with 57% of total users in Australia and 43% international in 2022.</p>\n \n <p>Of 466 survey responses, the most cited reason for eviQ use was <i>for information on side effects/toxicity</i> (67%). Ninety-three percent (93%) of respondents either agreed or strongly agreed that eviQ contributed to both <i>health professionals providing the best evidence-based treatment and care</i> and <i>improving the standardization of treatment and care provided</i>.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p> eviQ is embedded in Australian clinical practice, highly valued, and relied upon by users. Users agree that eviQ has a positive impact on patients by supporting the delivery of evidence-based treatment and that eviQ contributed to patients’ improved health outcomes and quality of life. eviQ's increasing international usage should be explored.</p>\n </section>\n </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14067","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

To understand the current usage of eviQ Cancer Treatments Online (www.eviQ.org.au), an Australian, open-access website providing evidence-based and consensus-driven cancer treatment protocols and information, and the extent to which it is meeting its intended outcomes and providing value to its users.

Methods

A mixed-method evaluation was conducted in 2020−2022 which included a review of key program documentation and website usage data, and delivery of a focused online survey to its users.

Results

In 2022, 329 clinicians representing all Australian states and territories contributed to eviQ content development and review. eviQ content continues to grow with a 15.2% increase in total content from 2019 to 2022.

eviQ website users continue to grow with 90,000 total monthly users in 2022, representing a 166% increase from 2018. The proportion of international users compared to Australian users continues to grow with 57% of total users in Australia and 43% international in 2022.

Of 466 survey responses, the most cited reason for eviQ use was for information on side effects/toxicity (67%). Ninety-three percent (93%) of respondents either agreed or strongly agreed that eviQ contributed to both health professionals providing the best evidence-based treatment and care and improving the standardization of treatment and care provided.

Conclusion

eviQ is embedded in Australian clinical practice, highly valued, and relied upon by users. Users agree that eviQ has a positive impact on patients by supporting the delivery of evidence-based treatment and that eviQ contributed to patients’ improved health outcomes and quality of life. eviQ's increasing international usage should be explored.

查看原文本刊更多论文

eviQ 癌症治疗在线：提供循证信息，改善癌症患者的治疗效果

目的了解 eviQ Cancer Treatments Online（www.eviQ.org.au）的当前使用情况，该网站是澳大利亚的一个开放式网站，提供基于证据和共识的癌症治疗方案和信息，以及该网站在多大程度上实现了预期成果并为用户提供了价值。方法在 2020-2022 年开展了一项混合方法评估，其中包括对主要计划文件和网站使用数据的审查，以及向用户提供一项重点在线调查。结果2022年，代表澳大利亚各州和地区的329名临床医生为eviQ内容的开发和审核做出了贡献。eviQ内容持续增长，从2019年到2022年，内容总量增长了15.2%。与澳大利亚用户相比，国际用户的比例继续增长，2022 年澳大利亚用户占总用户的 57%，国际用户占 43%。在 466 份调查回复中，使用 eviQ 的最主要原因是了解副作用/毒性信息（67%）。93%的受访者同意或非常同意eviQ有助于医疗专业人员提供最佳循证治疗和护理，并有助于提高治疗和护理的标准化水平。用户一致认为eviQ通过支持循证治疗对患者产生了积极影响，并认为eviQ有助于改善患者的健康状况和生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.